share_log

藥明康德:翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

HKEX ·  Sep 26 05:00

Summary by Moomoo AI

無錫藥明康德新藥開發股份有限公司於2024年9月26日提交了翌日披露報表,披露了公司在上海證券交易所進行的股份回購活動。根據報表,公司在2024年9月10日至9月26日期間,通過多次交易回購了總計約1.5萬股A股股份,回購價格範圍在RMB 38.31至RMB 43.32之間。該系列股份回購活動並未導致公司已發行股份總數的變動,結存股份數目維持在2,524,851,053股。公司確認,這些股份回購活動已獲得董事會正式授權批准,並遵守了所有適用的上市規則、法律及其他監管規定。股份回購後,公司未進行任何新股發行或庫存股份再出售或轉讓。
無錫藥明康德新藥開發股份有限公司於2024年9月26日提交了翌日披露報表,披露了公司在上海證券交易所進行的股份回購活動。根據報表,公司在2024年9月10日至9月26日期間,通過多次交易回購了總計約1.5萬股A股股份,回購價格範圍在RMB 38.31至RMB 43.32之間。該系列股份回購活動並未導致公司已發行股份總數的變動,結存股份數目維持在2,524,851,053股。公司確認,這些股份回購活動已獲得董事會正式授權批准,並遵守了所有適用的上市規則、法律及其他監管規定。股份回購後,公司未進行任何新股發行或庫存股份再出售或轉讓。
Wuxi Apptec submitted the next day disclosure report on September 26, 2024, disclosing the company's share repurchase activities on the Shanghai Stock Exchange. According to the report, between September 10 and September 26, 2024, the company repurchased approximately 0.015 million shares of A shares through multiple trades, with repurchase prices ranging from RMB 38.31 to RMB 43.32. This series of share repurchase activities did not result in any change in the total number of issued shares of the company, and the remaining number of shares was maintained at 2,524,851,053 shares. The company confirmed that these share repurchase activities had obtained formal approval from the board of directors and complied with all applicable listing rules, laws, and other regulatory requirements. Following the share repurchase, the company did not carry out any new share issuance or resell or transfer of treasury shares.
Wuxi Apptec submitted the next day disclosure report on September 26, 2024, disclosing the company's share repurchase activities on the Shanghai Stock Exchange. According to the report, between September 10 and September 26, 2024, the company repurchased approximately 0.015 million shares of A shares through multiple trades, with repurchase prices ranging from RMB 38.31 to RMB 43.32. This series of share repurchase activities did not result in any change in the total number of issued shares of the company, and the remaining number of shares was maintained at 2,524,851,053 shares. The company confirmed that these share repurchase activities had obtained formal approval from the board of directors and complied with all applicable listing rules, laws, and other regulatory requirements. Following the share repurchase, the company did not carry out any new share issuance or resell or transfer of treasury shares.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more